M A RC H 1 3 - 1 7 , 2 0 1 9FAIRMONT CHÂTEAU, WHISTLERBRITISH C OLUMBIA, CANADA

SUMMIT CHAIRS:Steve Coutré, MDProfessorStanford UniversityStanford, CA

Joseph Mikhael, MD, MEd, FRCPC, FACP Professor, Applied Cancer Research and Drug Discovery Translational Genomics Research Institute at City of Hope Duarte, CA

Richard Stone, MDProfessor of Medicine Director, Translational Research, Adult Leukemia ProgramDana-Farber Cancer Institute/ Harvard Medical SchoolBoston, MA

Andrew Zelenetz, MD, PhDMedical Director, Quality InformaticsMemorial Sloan Kettering Cancer CenterNew York, NY

6th Annual Global Summit on

MalignanciesHEMATOLOGIC

http://bit.ly/Whistler2019For more information and to REGISTER visit:

M A RC H 1 3 - 1 7 , 2 0 1 9FAIRMONT CHÂTEAU, WHISTLER

BRITISH C OLUMBIA, CANADA

6th Annual Global Summit on

MalignanciesHEMATOLOGIC

Kenneth Anderson, MDProgram Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma TherapeuticsDana-Farber Cancer InstituteBoston, MA

David Avigan, MDCo-Director, Immunotherapy InstituteBeth Israel Deaconess Medical CenterBoston, MA

Veronika Bachanova, MDAssociate Professor of MedicineUniversity of MinnesotaMinneapolis, MN

Connie Batlevi, MD, PhDAssistant Attending PhysicianMemorial Sloan Kettering Cancer CenterNew York, NY

William Bensinger, MDDirector, Myeloma ProgramSwedish Cancer CenterSeattle, WA

Prithviraj Bose, MBBSAssociate ProfessorUniversity of Texas MD Anderson Cancer CenterHouston, TX

Jennifer Brown, MD, PhDDirector, Chronic Lymphocytic Leukemia CenterAssociate Professor of MedicineHarvard Medical School/Dana-Farber Cancer InstituteBoston, MA

Steven Coutré, MD CHAIRProfessor of MedicineStanford University Cancer CenterStanford, CA

Alexey V. Danilov, MD, PhDAssociate Professor of MedicineOregon Health and Science University Portland, OR

Naval Daver, MDAssociate ProfessorDirector of Leukemia Research Alliance Program University of Texas MD Anderson Cancer CenterHouston, TX

Sven De Vos, MD, PhDAssociate ProfessorDavid Geffen School of Medicine at UCLALos Angeles, CA

Courtney DiNardo, MD, MSCEAssistant ProfessorUniversity of Texas MD Anderson Cancer CenterHouston, TX

Brian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramTaussig Cancer InstituteCleveland, OH

Michael Keating, MDProfessorUniversity of Texas MD Anderson Cancer CenterHouston, TX

John Kuruvilla, MD, FRCPCAssistant ProfessorUniversity of TorontoToronto, Canada

Mark Levis, MD, PhDProfessorJohns Hopkins UniversityBaltimore, MD

Matthew Lunning, DO, FACPAssociate ProfessorUniversity of NebraskaOmaha, NE

David Maloney, MD, PhDProfessor of Medicine University of Washington/Fred Hutchinson Cancer CenterSeattle, WA

Thomas Martin, MDProfessorUniversity of California, San FranciscoHelen Diller Family Comprehensive Cancer CenterSan Francisco, CA

Anthony Mato, MD, MSCEDirector, CLL ProgramMemorial Sloan Kettering Cancer CenterNew York, NY

Soheil Meshinchi, MD, PhDProfessor of MedicineFred Hutchinson Cancer CenterSeattle, WA

Joseph Mikhael, MD, MEd, FRCPC, FACP CHAIRProfessor, Applied Cancer Research and Drug DiscoveryTranslational Genomics Research Institute at City of Hope Duarte, CA

David Miklos, MD, PhDClinical Director of Cancer Cell TherapyAssociate Professor of MedicineStanford UniversityStanford, CA

John Pagel, MD, PhDChief of Hematologic MalignanciesSwedish Cancer InstituteSeattle, WA

Krina Patel, MDAssistant ProfessorUniversity of Texas MD Anderson Cancer CenterHouston, TX

Krish Patel, MDOncologistSwedish Medical CenterSeattle, WA

Naveen Pemmaraju, MDAssociate Professor of MedicineUniversity of Texas MD Anderson Cancer CenterHouston, TX

Alexander Perl, MDAssociate ProfessorUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia, PA

Tycel Phillips, MDAssociate ProfessorUniversity of Michigan MedicineAnn Arbor, MI

David Porter, MDJodi Fisher Horowitz Professor in Leukemia Care ExcellenceUniversity of Pennsylvania Medical CenterPhiladelphia, PA

Radhakrishnan Ramchandren, MDAssociate ProfessorKarmanos Cancer InstituteDetroit, MI

Farhad Ravandi-Kashani, MDProfessor of MedicineChief, Section of Developmental TherapeuticsUniversity of Texas MD Anderson Cancer CenterHouston, TX

Sarah Rutherford, MDAssistant ProfessorWeill Cornell MedicineNew York, NY

Stephen Schuster, MDProfessor of MedicineUniversity of PennsylvaniaPhiladelphia, PA

Nina Shah, MDAssociate ProfessorUniversity of California San FranciscoSan Francisco, CA

Jeff Sharman, MDMedical Director, Hematology ResearchThe US Oncology NetworkEugene, OR

Edward Stadtmauer, MDSection Chief, Hematologic Malignancies, Roseman, Tarte, Harrow,andShafferFamilies’ President’sDistinguishedProfessorUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia, PA

Deborah Stephens, DOAssistant ProfessorUniversity of UtahSalt Lake City, UT

Richard Stone, MD CHAIRProfessor of MedicineDirector, Translational Research, Adult Leukemia ProgramDana-Farber Cancer Institute/Harvard Medical SchoolBoston, MA

Steven Treon, MDDirector,BingCenterforWaldenström’s MacroglobulinemiaDana-Farber Cancer InstituteBoston, MA

Ravi Vij, MD, MBAProfessor of MedicineWashington University School of Medicine in St. LouisSt. Louis, MO

Roland Walter, MDAssociate Member Fred Hutchinson Cancer Reserach CenterSeattle, WA

Eunice Wang, MDChief, Leukemia ServiceRoswell Park Cancer InstituteBuffalo, NY

Adrian Wiestner, MD, PhDSenior InvestigatorsNIH National Heart, Lung, and Blood InstituteBethesda, MD

Andrew Zelenetz, MD, PhD CHAIRMedical Director, Quality InformaticsMemorial Sloan Kettering Cancer CenterNew York, NY

Jeffrey Zonder, MDProfessor of Oncology Barbara Ann Karmanos Cancer Institute Detroit, MI

FACULTY

M A RC H 1 3 - 1 7 , 2 0 1 9FAIRMONT CHÂTEAU, WHISTLER

BRITISH C OLUMBIA, CANADA

6th Annual Global Summit on

MalignanciesHEMATOLOGIC

Wednesday, March 13, 2019Setting the Stage

5:00 PM Welcome and Introductions

5:15 PM How to Limit the Impact of CLL on Patients' Lives Michael Keating

5:30 PM Can We Finally Start Sub-setting DLBCL in 2019? Sven De Vos

5:45 PM Key Advances in the Treatment of Hodgkin's Disease in 2019

Rod Ramchandren

6:00 PM How Do We Get to the Next Inflection Point in MM? Kenneth Anderson

6:15 PM BREAK

6:30 PM FLT3 Madness: Anarchy in Clinical Trials Charles Schiffer

6:45 PM What's New in AML: How to Develop New Drugs in AML

Alexander Perl

7:00 PM Targeting the Mitochondria in B-cell Malignancies Alexey Danilov

7:15 PM DISCUSSION AND CASE STUDIES

8:00 PM ADJOURN TO WELCOME RECEPTION

Thursday, March 14, 20196:00 AM BREAKFAST

Chronic Lymphocytic Leukemia7:00 AM CLL Combinations: Is the Whole Greater than the

Sum of the Parts? Anthony Mato

7:15 AM How Can We Overcome the Immunosuppressive Microenvironment in CLL?

Veronika Bachanova

7:30 AM MRD in CLL: How Deep Should We Go? TBD

7:45 AM DISCUSSION

8:00 AM Overcoming Primary and Acquired Resistance to BTKi in WM

Steven Treon

8:15 AM Influence of BTK on Immune Function: Mechanisms of Resistance

Adrian Wiestner

8:30 AM Updated Results: Next-generation BTKi John Pagel

8:45 AM What are the Next Steps for Ibrutinib in CLL? Jennifer Brown*

9:00 AM DISCUSSION

9:15 AM BREAK

9:30 AM Update on Murano Data (R/R vs. BR)* Steven Coutr�*

9:45 AM Next Steps for Venetoclax in Combination* TBD

10:00 AM Venetoclax: Impact of Early Intervention in CLL Deborah Stephens

10:15 AM Emerging Data on PI3K Resistance in CLL Jennifer Brown

10:30 AM DISCUSSION AND CASE STUDIES

11:00 AM BREAK

Biotech Showcases11:10 AM Biotech Showcase #1

11:20 AM Biotech Showcase #2

11:30 AM Biotech Showcase #3

11:40 AM Biotech Showcase #4

11:50 AM Biotech Showcase #5

12:00 PM ADVISORY BOARDS

Debating Technology: Is There a Role for Chemotherapy in CLL?

5:00 PM Chemo-free Options: The Future of CLL Treatment Michael Keating*

5:10 PM Chemotherapy is Not Dead in CLL Andrew Zelenetz*

5:20 PM PANEL DISCUSSION: JENNIFER BROWN, STEVEN COUTRE, AND JOHN PAGEL

Lymphomas6:00 PM Ibrutinib and Venetoclax in Frontline DLBCL Sven de Vos

6:15 PM Polatuzumab in DLBCL Jeff Sharman

6:30 PM The Role of Non-chemotherapy Options in MCL Tycell Phillips

6:45 PM Approach to Patients with FL in Early Transformation

Brian Hill

7:00 PM Development of Rational Combinations with PI3K in Heme Malignancies

Matthew Lunning

7:15 PM Personalized Cancer Vaccines in Heme Malignancies

David Avigan

7:30 PM DISCUSSION

8:00 PM CASE STUDIES

8:30 PM ADJOURN TO POSTER RECEPTION

Friday, March 15, 20196:00 AM BREAKFAST

Multiple Myeloma7:00 AM How Many Drugs Do We Need in First-line

Myeloma? Nina Shah

7:15 AM What's Next for CAR-T in MM? Edward Stadtmauer

7:30 AM Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma

Ravi Vij

7:45 AM DISCUSSION

8:00 AM Role of Daratumumab in Frontline Multiple Myeloma

TBD

8:15 AM Understanding Immune Resistance to Daratumumab in Myeloma

Nizar Bahlis

8:30 AM What Role will Isatuximab Play in Multiple Myeloma?

Joseph Mikhael

8:45 AM What is Next with CD38 Antibodies? Krina Patel

9:00 AM DISCUSSION

9:15 AM BREAK

9:30 AM Where is Selinexor Going to Fit in the Multiple Myeloma Landscape?

Nizar Bahlis*

9:45 AM Will Venetoclax also be a Multiple Myeloma Drug? TBD

10:00 AM Status of Anti-fibril Therapy (Monoclonal Antibodies) in AL Amyloidosis

Jeffrey Zonder

10:15 AM DISCUSSION

Biotech Showcases10:30 AM Biotech Showcase #6

10:45 AM Biotech Showcase #7

11:00 AM DISCUSSION

11:30 AM CASE STUDIES

12:00 PM ADVISORY BOARDS

*Indicatesawaitingconfirmation

M A RC H 1 3 - 1 7 , 2 0 1 9FAIRMONT CHÂTEAU, WHISTLER

BRITISH C OLUMBIA, CANADA

6th Annual Global Summit on

MalignanciesHEMATOLOGIC

Debating Technology: Future Role of T-cell Engagers (CAR-T vs. Bispecifics)

5:00 PM CAR-T: The Technology of the Future Edward Stadtmauer*

5:10 PM Bi/Ti-specific Antibodies: The Optimal Way to Engage T-cells

Farhad Ravandi-Kashani

5:20 PM PANEL DISCUSSION: KENNETH ANDERSON, NINA SHAH, AND ANDREW ZELENETZ

Acute Myeloid Leukemia6:00 PM Understanding the Biology of Hereditary AML Courtney

DiNardo

6:15 PM Is the Age of 7+3 Coming to an End? Eunice Wang

6:30 PM Novel Agents: Beyond JAK Inhibition in Myelofibrosis

Prithviraj Bose

6:45 PM DISCUSSION

7:00 PM BCL2 Inhibition in AML: The New Standard of Care?

Michael Andreeff

7:15 PM Venetoclax-based Existing and Upcoming Combinations

Naval Daver

7:30 PM Increasing Remissions in BPDCN with IL-3 Receptor Targeting

Naveen Pemmaraju

7:45 PM Patient Case in 2023: The Future of Treating CLL and AML

David Porter

8:00 PM DISCUSSION

8:30 PM ADJOURN TO RECEPTION

Saturday, March 16, 20196:00 AM BREAKFAST

Emerging Trends in Lymphoma and CLL7:00 AM HCK Inhibition in MYD88 Diseases Steven Treon

7:15 AM Selinexor: Current and Future Combinations (Karyopharm)

Sarah Rutherford

7:30 AM TBD: Richter's Transformation TBD

7:45 AM DISCUSSION

8:00 AM Armored CAR-T Cells in R/R NHL and CLL Including Richter's Transformation

Connie Batlevi

8:15 AM Role of PD-1 and PD-L1 Therapy in Hodgkin's Lymphoma

John Kuruvilla

8:30 AM Incorporating Novel Therapeutics in Hodgkin's Lymphoma

Rod Ramchandren

8:45 AM DISCUSSION

9:15 AM Role of Brentuximab Vedotin with Chemotherapy for CD30(+) Peripheral T-cell Lymphoma (ECHELON-2)*

TBD

10:00 AM DISCUSSION

10:30 AM BREAK

Biotech Showcases10:45 AM Biotech Showcase: Syk: Can it Rise from the

Dead? Jeff Sharman

10:55 AM Biotech showcase #9

11:10 AM Biotech showcase #10

11:20 AM DISCUSSION

11:45 AM CASE STUDIES

12:00 PM ADVISORY BOARDS

Debating Technology: Utilizing Current CAR-T Therapy vs. Optimizing Future CARs

5:00 PM Finding a Role for Current CAR-T Technology William Bensinger

5:10 PM Necessity of Optimizing CAR-T Technology Thomas Martin

5:20 PM PANEL DISCUSSION: JOSEPH MIKHAEL, DAVID PORTER, AND EDWARD STADTMAUER

Emerging Trends in AML and MM6:00 PM Feasibility of CART Thearpy for R/R DLBCL

Patients in the Real WorldKrish Patel

6:15 PM Armored Monoclonal Antibodies in AML Roland Walter

6:30 PM Identifying Immunogenic Targets in AML Soheil Meshinchi

6:45 PM T-cell Based Therapies in AML Naval Daver

7:00 PM DISCUSSION

7:15 PM Treatment Sequencing in Patients with R/R MM after Daratumumab

Ravi Vij*

7:30 PM DISCUSSION

8:00 PM Role of FLT3 Post-transplant in AML TBD

8:15 PM Role of Single-agent FLT3 Inhibition TBD

8:30 PM Future Role of Combination Therapy with FLT3 Inhibition in AML

TBD

8:45 PM CASE STUDIES

9:00 PM ADJOURN

Sunday, March 17, 20196:00 AM BREAKFAST

Oral Abstracts7:00 AM Oral Abstract #1

7:15 AM Oral Abstract #2

7:30 AM Oral Abstract #3

7:45 AM Oral Abstract #4

8:00 AM Oral Abstract #5

8:15 AM Oral Abstract #6

8:30 AM ADJOURN

*Indicatesawaitingconfirmation